ACHV — ACHIEVE LIFE SCIENCES, INC.

—
Nasdaq · Health Care · Life Sciences Tools & Services · CIK 949858 ·
Last close
$6.06
Market Cap
$666.81M
52W High
$6.55
52W Low
$5.93
ADV30
889,263
Next earnings
2026-11-10
Achieve Life Sciences, Inc., doing business as AchieveRx, The Quit Company, a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -20,535,000 -12,110,000 206,423,000 59,736,000 25,694,000
Jun 2026 0 — -18,392,000 -74,769,000 190,439,000 47,958,000 205,115,000
Mar 2026 0 — -10,463,000 -10,168,000 33,105,000 28,078,000 22,427,000
Dec 2025 0 — -14,731,000 -14,662,000 41,790,000 20,909,000 20,272,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-44,043,000
Investing CF
$-124,477,000
Financing CF
$196,323,000
CapEx
$-33,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.38
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-357,273,000
Inventory
—
Receivables
—
ST Investments
$141,782,000
EBIT TTM
$-110,649,000
Pretax Income TTM
$-111,709,000
Interest Exp TTM
$1,060,000
Analysts
12

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -54,880,000 -54,648,000 41,790,000 20,272,000 21,518,000 -49,465,000
Dec 2024 0 -39,069,000 -39,827,000 38,633,000 17,734,000 20,899,000 -29,770,000
Dec 2023 0 -27,250,000 -29,815,000 19,371,000 20,819,000 -1,448,000 -24,479,000
Dec 2022 0 -40,800,000 -42,350,000 29,971,000 21,668,000 8,303,000 -37,569,000

TTM Snapshot

Revenues TTM
$2,754,000
NetIncome TTM
$-114,040,000
OpCashFlow TTM
—
Assets (Latest)
$190,439,000
Forward EPS
$-0.77

Max Pain — expiry 2026-12-18

max pain strike: $5.00 · spot: $6.78 · call oi: 25,957 · put oi: 203
Expected Move to 2026-12-18: ±$1.76 (25.96%) — implied range $5.02 – $8.54 · ATM straddle on $7.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
QDEL QuidelOrtho Corp $677.21M $9.87 —
QUIT ACHIEVE LIFE SCIENCES, INC. $630.99M $6.12 —
OABI OmniAb, Inc. $736.59M $5.05 —
NRC NRC HEALTH $549.32M $25.89 —
MYGN MYRIAD GENETICS INC $530.18M $5.54 —

News headlines (Yahoo Finance, 1h cache)

QUIT: Looking Ahead to Resubmission
2026-11-18 14:02 · Yahoo
Achieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT
2026-11-09 13:00 · Yahoo
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
2026-11-02 13:30 · Yahoo
Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
2026-10-21 12:30 · Yahoo
Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications
2026-10-07 12:30 · Yahoo
Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
2026-09-28 12:30 · Yahoo
ACHV: Looking Ahead to Resubmission
2026-08-18 10:21 · Yahoo
Achieve Life Sciences Stock Has Nearly Tripled in the Last Year. Now It Just Needs to Turn a Profit.
2026-08-12 17:10 · Yahoo
Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-11 12:30 · Yahoo
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
2026-07-31 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.